Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Chemotherapy-induced neuropathy is one of the most serious non-life-threatening side effects experienced by patients receiving this group of pharmaceutical agents. Although frequently reversible, some patients may remain with symptoms for the remainder of their lives. Early recognition that "numbness and tingling" in the hands and feet of a patient receiving chemotherapy is due to the antineoplastic drug, with subsequent dose reduction or discontinuation of the offending agent, may prevent the development of serious neurologic dysfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Floyd JD, Nguyen DT, Lobins RL, et al.: Cardiotoxicity of cancer therapy. J Clin Oncol 2005, 23:7685–7696.

    Article  PubMed  CAS  Google Scholar 

  2. Kaldor JM, Day NE, Pettersson F, et al.: Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990, 322:1–6.

    Article  PubMed  CAS  Google Scholar 

  3. Travis LB, Holowaty EJ, Bergfeldt K, et al.: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999, 340:351–357.

    Article  PubMed  CAS  Google Scholar 

  4. Cavalatti G, Marzorati L, Bogliun G, et al.: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69:203–207.

    Article  Google Scholar 

  5. Visovsky C: Chemotherapy-induced peripheral neuropathy. Cancer Invest 2003, 21:439–451.

    Article  PubMed  Google Scholar 

  6. Warner E: Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 1995, 5:161–169.

    Article  PubMed  Google Scholar 

  7. Tuxen MK, Hansen SW: Complications of treatment: neurotoxicity to anti-neoplastic drugs. Cancer Treat Rev 1994, 20:191–214.

    Article  PubMed  CAS  Google Scholar 

  8. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 349:9–17. Excellent review of chemotherapy-induced peripheral neuropathy.

    Article  Google Scholar 

  9. Peltier AC, Russell JW: Recent advanced in drug-induced neuropathies. Curr Opin Neurol 2002, 15:633–638.

    Article  PubMed  Google Scholar 

  10. Roberts JA, Jenison EL, Kim KM, et al.: A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997, 67:172–177.

    Article  PubMed  CAS  Google Scholar 

  11. Mollman JE: Cisplatin neuropathy. N Engl J Med 1990, 332:126–127.

    Article  Google Scholar 

  12. Moore DH, Donnelly J, McGuire WP, et al.: Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase-II study of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:4207–4213. An interesting clinical model for testing the potential clinical relevance of an agent claimed to be neuroprotective.

    Article  PubMed  CAS  Google Scholar 

  13. Postma TJ, Heimans JJ, Muller MJ: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739–744.

    Article  PubMed  CAS  Google Scholar 

  14. Markman M: Limits to the "benefits" from our oncologic interventions: a case report. Gynecol Oncol 2000, 78:261–262.

    Article  PubMed  CAS  Google Scholar 

  15. Di Maio M, Iaffaioli RV, de Placido de S, et al.: Residual neurotoxicity in patients with ovarian cancer in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trials in Ovarian cancer (MITO-4) retrospective study. J Clin Oncol 2005, 23(suppl):458s.

    Google Scholar 

  16. Pace A, Savarese A, Picardo M, et al.: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 1993, 21:927–931. Randomized phase-III trial demonstrating potential benefits of vitamin E, but it is of insufficient size to draw any definitive conclusions.

    Article  CAS  Google Scholar 

  17. Argyriou AA, Chroni E, Koutras A, et al.: Vitamin E for prophylaxis against chemotherapy-induced neuropathy. Neurology 2005, 64:26–31. Randomized phase-III trial demonstrating potential benefits of vitamin E, but is of insufficient size to draw any definitive conclusions.

    PubMed  CAS  Google Scholar 

  18. Forman AD: Peripheral neuropathy and cancer. Curr Oncol Rep 2004, 6:20–25.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas M.D. Anderson Cancer Center (Mail Box #121), 1515 Holcombe Boulevard, 77030, Houston, TX, USA

    Maurie Markman MD

Authors
  1. Maurie Markman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated. Current Science Inc 10, 275–278 (2006). https://doi.org/10.1007/s11916-006-0032-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-006-0032-0

Keywords

Search

Navigation